Daily Respiratory Research Analysis
Analyzed 209 papers and selected 3 impactful papers.
Summary
Three impactful studies advanced respiratory science and care: a Science report identifies human STING–NF-κB signaling as a barrier to avian influenza spillover; a Thorax analysis shows that high sleep apnea–specific hypoxic burden predicts residual sleep apnea on PAP; and a population-based study in Italy finds that seasonally targeted nirsevimab prophylaxis substantially reduces infant RSV hospitalizations. Together, they span mechanistic insight, physiology-guided risk stratification, and real-world prevention.
Research Themes
- Innate antiviral barriers and pandemic spillover prevention
- Physiology-based risk stratification in sleep-disordered breathing
- Real-world effectiveness of RSV immunoprophylaxis in infants
Selected Articles
1. STING-NF-κB signaling builds an influenza spillover barrier.
This mechanistic study identifies human STING as a barrier to avian influenza A virus spillover by activating NF-κB and downstream NF-κB–stimulated genes via a specific STING domain. The work reframes host innate signaling as a determinant of cross-species transmission.
Impact: Revealing a host-intrinsic pathway that blocks influenza spillover provides a novel paradigm and potential target for pandemic prevention.
Clinical Implications: While preclinical, the findings suggest strategies to potentiate STING–NF-κB signaling or mimic key NF-κB–stimulated genes could reduce zoonotic influenza risk and inform vaccine/adjuvant design.
Key Findings
- Human STING acts as a transmission barrier against avian influenza A viruses.
- STING activates NF-κB and downstream NF-κB–stimulated genes via a specific domain.
- Host innate signaling is implicated as a determinant of cross-species influenza transmission.
Methodological Strengths
- Rigorous mechanistic dissection of host-pathogen signaling.
- Identification of a specific STING domain mediating NF-κB activation.
Limitations
- Preclinical mechanistic study; clinical validation is lacking.
- Abstracted details on in vivo models and breadth across IAV strains are incomplete.
Future Directions: Define NSGs that confer the strongest restriction, validate findings in vivo across diverse IAV clades, and explore pharmacologic potentiation of STING–NF-κB pathways for pre-exposure prophylaxis.
Influenza pandemics are often traced back to the spillover of avian influenza A viruses (IAVs) to humans. However, barriers against IAV transmission remain elusive. We demonstrated human stimulator of interferon genes (STING) as a transmission barrier against IAVs. STING activated nuclear factor κB (NF-κB) and downstream NF-κB-stimulated genes (NSGs) through a specific domain. Among these NSGs,
2. Loop gain predicts residual sleep apnoea among people using positive airway pressure.
Across two large RCT cohorts, higher baseline loop gain independently predicted residual sleep apnea on PAP (adjusted OR≈2.2–3.3), even after accounting for central apnea. The physiology-based metric offers a practical way to identify patients at risk for PAP nonresponse.
Impact: Links a validated physiological trait to PAP outcomes, enabling targeted monitoring and adjunctive strategies (e.g., oxygen, acetazolamide).
Clinical Implications: Consider estimating loop gain pre-PAP to risk-stratify patients; high-LG phenotypes might benefit from adjunctive therapies that stabilize ventilatory control and from closer follow-up.
Key Findings
- High baseline loop gain independently predicted residual sleep apnea on PAP in two cohorts (APPLES aOR 2.17; RICCADSA aOR 3.31).
- Associations persisted after adjustment for measures of central sleep apnea.
- Linear modeling confirmed a continuous relationship between loop gain and residual AHI.
Methodological Strengths
- Use of two large randomized-trial cohorts with standardized PSG-derived physiology.
- Validated loop gain estimation; multivariable and sensitivity analyses.
Limitations
- Non-interventional design; causality cannot be proven.
- Outcome ascertainment differed between cohorts (PSG vs device downloads), potentially introducing heterogeneity.
Future Directions: Prospective trials testing LG-targeted adjuncts (oxygen, acetazolamide) in high-LG patients; integration of LG into clinical PAP decision algorithms.
RATIONALE: Residual sleep apnoea-defined by an Apnoea-Hypopnoea Index ≥10 events/hour-affects~20% of obstructive sleep apnoea patients treated with positive airway pressure therapy and poses a major clinical challenge. Ventilatory control instability is a plausible cause of residual sleep apnoea. Elevated loop gain (LG), a measure of ventilatory instability, may be a risk factor, but this has not been rigorously tested. OBJECTIVE: To assess whether high LG at baseline is associated with residual sleep apnoea on positive airway pressure therapy in two large, randomised control trials: Apnoea Positive Pressure Long-Term Efficacy Study (APPLES) and Randomised Intervention with CPAP in Coronary Artery Disease and OSA (RICCADSA). METHODS: LG was estimated from baseline polysomnography using a validated method. Residual sleep apnoea was defined using polysomnography on positive airway pressure at 2 months (APPLES) or device downloads at 3 months (RICCADSA). Logistic regression estimated the odds of residual sleep apnoea with high LG (highest quartile), adjusting for confounders. A sensitivity analysis was performed using linear regression, where both the exposure and outcome were defined continuously. MEASUREMENTS AND MAIN RESULTS: In the unadjusted analysis, high LG was associated with threefold odds of residual sleep apnoea in both samples. After adjustment, elevated odds persisted in both APPLES (2.17 (1.24-3.59)) and RICCADSA (3.31 (1.33-8.24)). Associations remained after accounting for measures of central sleep apnoea. Linear regression confirmed the association of LG and residual Apnoea-Hypopnoea Index. CONCLUSIONS: High LG is a significant risk factor for residual sleep apnoea on positive airway pressure therapy. Ventilatory control instability identified at baseline may warrant closer monitoring or the initiation of adjunctive therapies aimed at reducing LG and improving the therapeutic response.
3. Impact of Seasonal Nirsevimab Administration in Infants Born During the RSV Circulation Period on RSV-Related Hospitalizations: A Population-Based Study from Emilia-Romagna, Northern Italy.
In Emilia-Romagna, seasonally targeting nirsevimab to infants born during RSV circulation was associated with 48% lower hospitalization rates vs a pre-COVID reference and 64% lower vs the prior season. Benefits were consistent across months and strongest in the first 3–4 months of life.
Impact: Provides timely, real-world effectiveness data supporting seasonal, birth-cohort–targeted RSV immunoprophylaxis at a population scale.
Clinical Implications: Health systems can expect substantial reductions in infant RSV hospitalizations by implementing seasonally timed nirsevimab for infants born during circulation; prioritization of early months post-birth is key.
Key Findings
- Post-nirsevimab season showed IRR 0.36 vs 2023–2024 and IRR 0.52 vs 2018–2019 for RSV-related hospitalizations.
- Reductions were consistent across epidemic months and strongest during the first 3–4 months of life.
- Population-based, adjusted negative binomial models with hospital clustering support robustness.
Methodological Strengths
- Population-based design spanning multiple seasons with pre/post comparisons.
- Adjusted negative binomial regression with hospital-level clustering.
Limitations
- Observational design susceptible to residual confounding and secular changes.
- ICD-9-CM coding may misclassify RSV hospitalizations; individual-level immunization status not detailed.
Future Directions: Link individual nirsevimab exposure to outcomes, evaluate equity and access, and assess impact on severe endpoints (ICU, ventilation) and health economics.
BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in early infancy, with the greatest burden occurring in the first months of life. Following the COVID-19 pandemic, many countries experienced intensified RSV circulation. Nirsevimab, a long-acting monoclonal antibody providing season-long protection after a single dose, was introduced in Italy for the 2024-2025 RSV season and recommended for infants born during the period of RSV circulation. We evaluated the population-level impact of this seasonal nirsevimab strategy on RSV-related hospitalizations among young infants. METHODS: We conducted a population-based observational study using regional hospital discharge records from Emilia-Romagna, Northern Italy, spanning January 2017 to April 2025. Analyses were restricted to RSV seasons (October-March) and infants aged ≤180 days. RSV-related hospitalizations were identified using ICD-9-CM codes. Hospitalization rates were calculated per 100,000 person-days. Incidence rate ratios (IRRs) were estimated using negative binomial regression models adjusted for season, age group, and sex, with clustering at the hospital level. The post-nirsevimab season (2024-2025) was compared with the immediate pre-nirsevimab season (2023-2024) and a pre-COVID reference season (2018-2019). RESULTS: A total of 551 RSV hospitalizations occurred in the pre-COVID season, 753 in the pre-nirsevimab season, and 252 in the post-nirsevimab season. The post-nirsevimab season was associated with a substantial reduction in RSV-related hospitalization rates compared with both the pre-COVID season (IRR 0.52; 95% CI 0.41-0.66) and the pre-nirsevimab season (IRR 0.36; 95% CI 0.29-0.44). Reductions were observed consistently across epidemic months and were most pronounced during the first three to four months of life. CONCLUSIONS: Seasonal administration of nirsevimab to infants born during the RSV circulation period was associated with a marked and sustained reduction in RSV-related hospitalizations in early infancy. These findings support the effectiveness of targeted, seasonally timed infant immunoprophylaxis as a population-level RSV prevention strategy.